Emerging treatments
Phase 1 study of tabalumab, a human anti-B-cell activating factor antibody, and bortezomib in patients with relapsed/refractory multiple myeloma. Raje N et al. Clin Cancer Res. 2016 Jun 10. pii: clincanres.0201.2016. [Epub ahead of print]. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Lesokhin AM et al. J Clin Oncol. 2016 Jun 6. pii:…